Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 14/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18803184 | 0.89 | ELANE (0.44) | ELANERIPK1 | |
| SCHEMBL22139593 | 0.81 | ELANE (0.38) | ELANEKMT2AMAPTRIPK1 | |
| SCHEMBL12342059 | 0.79 | KDM4E (0.42) | MAPTLMNA | |
| SCHEMBL14310955 | 0.78 | ELANE (0.42) | ELANEKMT2AAKR1B1MAPT | |
| SCHEMBL12027013 | 0.76 | ELANE (0.45) | ELANEKMT2AMAPT | |
| SCHEMBL19360006 | 0.75 | KMT2A (0.36) | MEN1KMT2AMAPTLMNA | |
| SCHEMBL19105004 | 0.75 | ELANE (0.37) | ELANEMEN1KMT2AMAPTNPSR1 | |
| SCHEMBL12793115 | 0.75 | ELANE (0.41) | ELANE | |
| SCHEMBL20466175 | 0.73 | — | — | |
| SCHEMBL319016 | 0.73 | CA1 (0.39) | MAPTRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827661-B2 | Water soluble fluorescent or colored dyes comprising conjugating groups | Sony Group Corporation (JP) | 2023-11-28 | — | — | US | disclosed |
| US-11779649-B2 | Antibodies to PMEL17 and conjugates thereof | NOVARTIS AG (CH) | 2023-10-10 | — | — | US | disclosed |
| US-11779649-B2 | Antibodies to PMEL17 and conjugates thereof | NOVARTIS AG (CH) | 2023-10-10 | — | — | US | disclosed |
| US-11685835-B2 | Ultra bright dimeric or polymeric dyes | SONY CORPORATION (JP) | 2023-06-27 | — | — | US | disclosed |
| US-20230129481-A1 | ULTRA BRIGHT DIMERIC OR POLYMERIC DYES WITH SPACING LINKER GROUPS | Sony Group Corporation (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20200197528-A1 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2020-06-25 | — | — | US | disclosed |
| US-9938323-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | NOVARTIS AG (CH) | 2018-04-10 | — | — | US | disclosed |
| US-9884817-B2 | Auristatin derivatives and conjugates thereof | NOVARTIS AG (CH) | 2018-02-06 | — | — | US | disclosed |
| US-9851359-B2 | Ultra bright dimeric or polymeric dyes with spacing linker groups | SONY CORPORATION OF AMERICA (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
| US-9714261-B2 | Ionic liquid supported organotin reagents for the manufacturing of radiopharmaceuticals compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-07-25 | — | — | US | disclosed |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20160326194-A1 | IONIC LIQUID SUPPORTED ORGANOTIN REAGENTS FOR THE MANUFACTURING OF RADIOPHARMACEUTICALS COMPOUNDS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11779649-B2 | Antibodies to PMEL17 and conjugates thereof | GNA15, GNA11, EEA1 | ELANE 1843/4885MEN1 670/4885KMT2A 864/4885 |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | ELANE 627/4885MEN1 1913/4885KMT2A 2505/4885 |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | AURKC, AURKA, AURKB | ELANE 3067/4885MEN1 986/4885KMT2A 3167/4885 |
| US-11827661-B2 | Water soluble fluorescent or colored dyes comprising conjugating groups | CHRM1, CHRM2, H1-0 | ELANE 3180/4885MEN1 478/4885KMT2A 3330/4885 |
| US-20160326194-A1 | IONIC LIQUID SUPPORTED ORGANOTIN REAGENTS FOR THE MANUFACTURING OF RADIOPHARMACEUTICALS COMPOUNDS | KIT, NISCH, FLT3 | ELANE 4152/4885MEN1 17/4885KMT2A 606/4885 |
| US-20230129481-A1 | ULTRA BRIGHT DIMERIC OR POLYMERIC DYES WITH SPACING LINKER GROUPS | IK, MTCL3, RRM1 | ELANE 4193/4885MEN1 1209/4885KMT2A 2550/4885 |
| US-20200197528-A1 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | GNA15, GNA11, EEA1 | ELANE 1984/4885MEN1 236/4885KMT2A 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.